# Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke

> **NCT01464788** · PHASE2 · TERMINATED · sponsor: **Andrew D. Barreto, MD** · enrollment: 90 (actual)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** Low Dose Argatroban
- **DRUG:** High Dose Argatroban
- **DRUG:** rt-PA (alteplase)

## Key facts

- **NCT ID:** NCT01464788
- **Lead sponsor:** Andrew D. Barreto, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2015-06-11
- **Final completion:** 2015-06-11
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** The study was halted prematurely at 90 of 105 planned patients due to the beneficial results of embolectomy clinical trials.
- **Last updated:** 2017-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01464788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01464788, "Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01464788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*